Kennedy et al. observed a significant increase in anti-S-IgG levels five weeks after a third mRNA vaccination (homologous regimen) in a cohort of 918 IBD patients receiving anti-TNF therapy and 442 patients receiving vedolizumab therapy compared to values after the second vaccination. The gene discussed is TNF; the disease is inflammatory bowel disease.